References
- Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281(1): 61–6
- Lederberg J, Shope RE, Oaks SC, eds. Emerging infections: microbial threats to health in the United States. Washington, DC: National Academy Press, 1992
- Centers for Disease Control and Prevention. Addressing emerging infectious disease threats: a prevention strategy for the United States. Atlanta, Ga: US Dept of Health and Human Services, Public Health Service, 1994
- Centers for Disease Control and Prevention. Preventing emerging infectious diseases: a strategy for the 21st century. Atlanta, Ga: US Dept of Health and Human Services, Public Health Service, 1998
- Committee on Infectious Diseases, American Academy of Pediatrics, Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Meningococcal disease prevention and control strategies for practice-based physicians. Pediatrics 1996; 97(3): 404–12
- Moore KA, Osterholm MT. Meningococcal disease and public health practice: a complicated toad map. JAMA 1998; 279(6): 472–3
- Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulse-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33(9): 2233–9
- Centers for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46(RR-5): 13–21
- Performance standards for antimicrobials susceptibility testing: 9th informational supplement. Villanova, Pa: National Committee for Clinical Laboratory Standards, 1999; Document No. M100-S9
- Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): a strategy from the DRSP Working Group. JAMA 1996; 275(3): 206–9
- Centers for Disease Control and Prevention. Prevention of pneuomococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46(RR-8): 1–24
- Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270(15): 1826–31
- Remington PL, Smith MY, Williamson DF, et al. Design, characteristics, and usefulness of state-based behavioral risk factor surveillance: 1981–87. Public Health Rep 1988; 103(4): 366–75
- Behavioral Risk Factor Surveillance Survey. Minneapolis: Center for Health Statistics, Minnesota Dept of Health, 1998
- Nichol KL, Mac Donald R, Hauge M. Factors associated with influenza and pneumococcal vaccination behavior among high-risk adults. J Gen Intern Med 1996; 11: 673–7
References
- Centers for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-5):13–21
- Harrison LH. The worldwide prevention of meningococcal infection: still an elusive goal. JAMA 1995;273(5):419–21
- Jackson LA, Schuchat A, Reeves MW, et al. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA 1995;273(5):383–9
- Rosenstein N, Levine O, Taylor JP, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998;279(6): 435–9